Antibodies | Dermatomyositis with Anti-MDA5 Antibodies Following SARS-CoV-2 mRNA Vaccination Treated with Tofacitinib: Integrating Literature Evidence and a Novel Observation

This case report describes a rare instance of newly developed anti-MDA5-positive dermatomyositis following the fourth dose of the BNT162b2 vaccine, highlighting atypical presentations without pulmonary involvement and demonstrating an excellent clinical response to tofacitinib, offering new insights into the mechanisms of vaccine-related autoimmune diseases and targeted therapeutic strategies.

 

Literature Overview

The article titled 'Dermatomyositis with Anti-MDA5 Autoantibodies After SARS-CoV-2 mRNA Vaccination Treated with Tofacitinib: Integrating Literature Evidence and a Novel Observation,' published in the journal Antibodies, reviews and summarizes the clinical features, treatment strategies, and potential mechanisms of anti-MDA5 antibody-positive dermatomyositis following SARS-CoV-2 mRNA vaccination, while also reporting a novel case. By systematically synthesizing existing literature and integrating both typical and atypical clinical phenotypes, the study emphasizes diagnostic challenges in the absence of interstitial lung disease and proposes JAK inhibitors as a potential therapeutic option, providing critical reference for understanding the heterogeneity and individualized management of vaccine-associated dermatomyositis.

Background Knowledge

Dermatomyositis (DM) is a systemic autoimmune disorder primarily characterized by inflammation of the skin and muscles. It can be subclassified based on specific autoantibody profiles, among which anti-MDA5 antibody-positive DM is particularly distinctive, often associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. MDA5 is an intracellular RNA sensor involved in viral RNA recognition and activation of the type I interferon pathway, whose aberrant activation is considered a core mechanism in anti-MDA5-associated DM. SARS-CoV-2 mRNA vaccines deliver mRNA encoding the spike protein, activating the host's innate immune system—especially the type I interferon response—which may break immune tolerance and trigger autoantibody production in genetically or immunologically susceptible individuals. Several case reports have indicated that mRNA vaccination may lead to new-onset or exacerbated dermatomyositis, particularly the anti-MDA5-positive subtype, although the clinical spectrum, onset time window, and optimal treatment strategies remain unclear. Tofacitinib, a JAK inhibitor, exerts immunomodulatory effects by blocking the type I interferon signaling pathway and has shown efficacy in refractory anti-MDA5-associated ILD. However, evidence remains limited regarding the presentation of post-vaccination anti-MDA5-DM without pulmonary involvement and its response to JAK inhibitors. This study fills knowledge gaps in this field concerning atypical phenotypes and targeted therapies through a new case and literature integration.

 

 

Research Methods and Experiments

This study employed a narrative literature review approach, systematically searching the PubMed/MEDLINE database for case reports and case series related to newly developed dermatomyositis following SARS-CoV-2 vaccination, with a focus on clinical features, autoantibody profiles, treatment regimens, and outcomes. Additionally, the research team reported a new case: a 60-year-old woman who developed typical skin manifestations (such as heliotrope rash, Gottron’s papules, V-sign, and mechanic’s hands) and polyarthralgia approximately two weeks after receiving the fourth dose of the BNT162b2 vaccine, but without muscle weakness or interstitial lung disease. Laboratory tests revealed positive ANA, positive anti-MDA5 and anti-Ro52 antibodies, and elevated inflammatory markers, while muscle enzymes remained normal. Skin biopsy showed interface dermatitis, and chest CT revealed no pulmonary abnormalities. The patient was treated with oral prednisone, intravenous alprostadil, and tofacitinib. Clinical symptoms significantly improved during follow-up until June 2025.

Key Conclusions and Perspectives

• Anti-MDA5 antibody-positive dermatomyositis can occur after SARS-CoV-2 mRNA vaccination; this study is the first to report its occurrence after the fourth dose, expanding the disease's temporal window
• Typical skin manifestations such as heliotrope rash, Gottron’s papules, and mechanic’s hands are key diagnostic clues, but the disease may present without interstitial lung disease or elevated muscle enzymes, increasing diagnostic difficulty
• Anti-MDA5 antibodies frequently coexist with anti-Ro52 antibodies and are more commonly observed in patients with pulmonary involvement, suggesting their role as serological markers of severe phenotypes
• Tofacitinib demonstrated significant efficacy in this case, supporting the JAK-STAT pathway as a therapeutic target in anti-MDA5-associated DM, especially for interferon-driven skin and joint manifestations
• Literature review indicates substantial clinical heterogeneity in post-vaccination anti-MDA5-DM, ranging from mild cutaneous forms to rapidly progressive ILD, necessitating individualized immunosuppressive strategies
• Although causality has not been definitively established, activation of the type I interferon pathway provides a plausible biological mechanism for vaccine-triggered autoimmunity

Research Significance and Prospects

This study underscores the need for vigilance regarding potential autoimmune disorders such as dermatomyositis following mRNA vaccination, especially when patients present with typical skin lesions, even in the absence of pulmonary or muscular involvement. Early detection of anti-MDA5 antibodies may aid in risk stratification and timely intervention. The use of tofacitinib offers a new treatment option for refractory or interferon-dominant cases, highlighting the potential of targeted therapies in vaccine-associated autoimmune diseases.

Future research should establish multicenter registries to systematically collect clinical and serological data on post-vaccination autoimmune disorders, clarifying incidence rates, risk factors, and natural disease courses. Furthermore, in-depth investigation into the interaction between host genetic backgrounds and vaccine-induced immune responses will help identify high-risk populations. Prospective studies on JAK inhibitors are urgently needed to validate their efficacy and safety in anti-MDA5-DM and optimize timing and dosing regimens.

 

 

Conclusion

This study integrates literature and a new case to systematically describe the clinical features and treatment responses of anti-MDA5 antibody-positive dermatomyositis following SARS-CoV-2 mRNA vaccination. Although rare, this condition may present with typical skin manifestations without pulmonary involvement, indicating that clinical diagnosis should incorporate serological testing. The emergence of anti-MDA5 antibodies may reflect aberrant activation of the type I interferon pathway, and tofacitinib effectively improves skin and joint symptoms by inhibiting JAK-STAT signaling, supporting its use as a targeted therapeutic strategy. While the causal relationship between vaccines and autoimmune diseases has not been fully established, the biological mechanism is plausible, suggesting that vaccines may act as environmental triggers in susceptible individuals. This study emphasizes vigilance toward post-vaccination autoimmune manifestations, advocates for individualized treatment approaches, and provides direction for future research, including the development of risk prediction models and clinical validation of targeted therapies, to optimize patient management and outcomes.

 

Maurizio Benucci, Elisa Cioffi, Francesca Li Gobbi, Maria Infantino, and Mariangela Manfredi. Dermatomyositis with Anti-MDA5 Autoantibodies After SARS-CoV-2 mRNA Vaccination Treated with Tofacitinib: Integrating Literature Evidence and a Novel Observation. Antibodies.